Introduction {#s1}
============

Eastern equine encephalitis (EEE) is the most severe arboviral disease with \>35% mortality in humans, especially in the \<15 and \>50 year-old populations ([@B1]--[@B4]). Eastern equine encephalitis virus (EEEV) is a member of *Togaviridae* family with positive-sense, single-stranded RNA genome ([@B5]). The EEEV life cycle is maintained in an enzootic cycle between *Culiseta melanura* mosquitoes that breed in freshwater hardwood swamp areas and birds ([@B4]). From 2007--2016, a total of 68 cases of neuroinvasive EEE were reported in the United States with an average of 7 cases per year ([@B6]). A recent study implicated Florida in a source-sink model as the major source of EEEV in eastern United States ([@B5]). Enzootic EEEV infection has also recently been reported in Panama ([@B7]). Mammalian infection of EEEV requires bridging mosquitoes that feed on both birds and mammals, such as the *Aedes* or *Coquillettidia* species ([@B4]). EEEV-infected humans typically do not develop a high enough viremia level to allow virus transmission to feeding mosquitoes, thus humans are considered dead-end hosts ([@B4]).

Most EEEV infections have no clinical symptoms and \< 5% of people infected with EEEV develop viral meningitis or encephalitis ([@B1]--[@B4]). Acute onset of fever, chills, malaise, myalgia, and arthralgia characterizes systemic EEEV infection ([@B4]). Neuroinvasive EEE is characterized by fever, headache, encephalopathy, and seizures ([@B1]). In addition to its high mortality rate, EEE results in neurologic sequelae in \>50% of survivors ([@B1]). Neuroimaging of EEE cases typically show abnormal MRI T2 weighted hyperintensities in the bilateral basal ganglia and thalami with associated restricted diffusion ([@B1], [@B8]). Meningeal enhancement is also frequently present. The diagnosis of EEE is made in the presence of positive EEEV IgM in the CSF ([@B1]). Intravenous immunoglobulin (IVIg) and high-dose IV methylprednisolone have been given in several isolated cases reported to have good outcomes, but the relationship between these patient outcomes and these interventions is unknown ([@B1], [@B9]--[@B11]).

The California serogroup virus is in the family *Bunyaviridae*, which includes the La Crosse virus (LACV), and is the most common cause of severe symptomatic disease in the pediatric population ([@B2], [@B6], [@B12], [@B13]). Clinical symptoms of La Crosse virus infection include fever, headache, vomiting, meningitis, encephalitis, and meningoencephalitis ([@B12], [@B14]). Mortality rate of La Crosse encephalitis is very low (\<1%) and most patients recover completely ([@B14]). Diagnosis of La Crosse virus is made in the presence of La Crosse virus IgM ([@B14]).

Case Presentation {#s2}
=================

A 57-year-old woman with a past medical history of hypertension, scoliosis and depression presented with 1 week of flu-like symptoms (diffuse body aches, fatigue, and chills) and generalized weakness that rapidly progressed over several days in June 2018. Her social history is significant for living in a trailer in a wooded area in Florida, living in areas close to a mix of salt and river water, and exposure to mold, rats, and bat droppings near her home. On initial neurological examination, the patient was lethargic but oriented to person, place and time. She had impaired concentration and required occasional tactile or auditory stimulus to maintain attention. There were no cranial nerve deficits. Strength was 4/5 in the bilateral upper extremities and 3/5 in the bilateral lower extremities. There were no pathologic reflexes and sensation to light touch was intact in all extremities. The patient then had a rapid deterioration requiring intubation and mechanical ventilation. Serum laboratory results and serology testing throughout the hospital course are presented in [Tables 1](#T1){ref-type="table"}--[6](#T6){ref-type="table"}. Ceftriaxone, acyclovir, vancomycin, and ampicillin were started due to suspicion of meningitis based on the initial clinical presentation and serum testing. Computed Tomography (CT) angiogram of the head was unremarkable. Initial MRI Brain without contrast (hospital day 1) showed abnormally increased T2 FLAIR signal in the deep gray nuclei bilaterally, most prominent in the striatum ([Figure 1](#F1){ref-type="fig"}). Blood cultures were negative throughout her hospitalization. Cerebrospinal fluid (CSF) analysis was suggestive of meningitis and is presented in [Table 5](#T5){ref-type="table"}. Her CSF arboviral antibody panel is shown in [Table 6](#T6){ref-type="table"} and was initially unremarkable except for California encephalitis IgG 1:256.

###### 

Urine drug screen.

                        **Ref. range**         **Hospital day 1**
  --------------------- ---------------------- -------------------------
  Amphetamine           Range: None detected   None detected
  Barbiturate           Range: None detected   None detected
  Benzodiazepine        Range: None detected   None detected
  Cannabinoid           Range: None detected   None detected
  Cocaine metabolites   Range: None detected   None detected
  Methadone screen      Range: None detected   None detected
  Opiate screen         Range: None detected   None detected
  Oxycodone             Range: None detected   None detected
  Ethyl alcohol         Range: Not detected    Below detectable limits

###### 

Serum metabolic panel.

                           **Ref. range**            **Hospital day 1**   **Hospital day 4**   **Hospital day 8**   **Hospital day 22**
  ------------------------ ------------------------- -------------------- -------------------- -------------------- ---------------------
  Sodium                   Range: 136--145 mmol/L    137                  136                  146 (H)              139
  Potassium                Range: 3.3--5.1 mmol/L    3.6                  4.6                  3.7                  3.4
  Chloride                 Range: 98--107 mmol/L     103                  109 (H)              111 (H)              102
  Carbon dioxide           Range: 22--30 mmol/L      23                   19 (L)               26                   30
  Urea nitrogen            Range: 6--21 mg/dL        12                   18                   14                   17
  Creatinine               Range: 0.38--1.02 mg/dL   0.87                 0.54                 0.34 (L)             0.43
  Glucose                  Range: 65--99 mg/dL       137 (H)              100 (H)              124 (H)              116 (H)
  Calcium                  Range: 8.4--10.2 mg/dL    8.8                  8.6                  8.4                  9.3
  Phosphorus               Range: 2.7--4.5 mg/dL     3.3                  3.6                  2.6 (L)              2.8
  Magnesium                Range: 1.5--2.8 mg/dL     2.0                  2.3                  2.2                  2.1
  Total protein            Range: 6.4--8.3 g/dL      7.0                                                            
  Albumin                  Range: 3.5--5.2 g/dL      4.1                                                            
  Albumin/globulin ratio   Latest units: (calc)      1.4                                                            
  AST                      Range: 0--37 IU/L         24                                                             
  ALT (SGPT)               Range: 0--35 IU/L         12                                                             
  Bilirubin, direct        Range: 0.0--0.2 mg/dL     \< 0.1                                                         
  Total bilirubin          Range: 0.0--1.0 mg/dL     0.4                                                            
  Alkaline phosphatase     Range: 33--133 IU/L       60                                                             

###### 

Complete blood counts, C-reactive protein.

                          **Ref. range**                **Hospital day 1**   **Hospital day 4**   **Hospital day 8**   **Hospital day 22**
  ----------------------- ----------------------------- -------------------- -------------------- -------------------- ---------------------
  WBC                     Range: 4.0--10.0 thou/cu mm   14.9 (H)             11.9 (H)             4.9                  8.1
  RBC                     Range: 4.00--5.20 x10E6/uL    4.97                 4.22                 3.51 (L)             3.81 (L)
  Hemoglobin              Range: 12.0--16.0 g/dL        14.9                 12.8                 10.8 (L)             11.6 (L)
  Hematocrit              Range: 35.0--45.0%            43.9                 37.5                 31.2 (L)             34.2 (L)
  MCV                     Range: 78.0--100.0 fl         88.3                 88.9                 89.0                 89.7
  MCH                     Range: 26.0--34.0 pg          29.9                 30.2                 30.7                 30.4
  MCHC                    Range: 31.0--37.0 g/dL        33.9                 34.0                 34.4                 33.9
  RDW                     Range: 11.0--14.0%            13.3                 13.7                 13.5                 13.6
  Platelet count          Range: 150--450 thou/cu mm    181                  193                  243                  491 (H)
  MPV                     Range: 6.0--10.0 fl           8.2                  9.2                  8.3                  8.4
  Neutrophils             Range: 40.0--80.0%            90.1 (H)             86.4 (H)             64.0                 66.8
  Lymphocytes             Range: 20.0--45.0%            4.9 (L)              6.2 (L)              20.2                 15.1 (L)
  Monocytes               Range: 2.0--10.0%             4.6                  7.2                  14.1 (H)             15.9 (H)
  Eosinophils             Range: 0.0--8.0%              0.0                  0.0                  1.5                  1.0
  Basophils               Range: 0.0--2.0%              0.4                  0.2                  0.2                  1.2
  CRP, high sensitivity   Range: 0.00--5.00 mg/L        10.96 (H)                                                      

###### 

CSF and urine infectious serology panel.

                                       **Ref. range**        **Hospital day 2**
  ------------------------------------ --------------------- --------------------
  Cryptococcal Ag CSF                  Range: Negative       Not detected
  Histoplasma antigen urine            Latest Units: ng/mL   Not detected
  Histoplasma galactomannan Ag urine   Range: Not detected   Not detected
  EBV quant interpretation CSF         Range: Not detected   Not detected
  Enterovirus PCR CSF                  Range: Negative       Negative
  HSV DNA PCR CSF                      Range: Not detected   Not detected
  Varicella zoster DNA PCR CSF         Range: Not detected   Not detected

###### 

Cerebrospinal fluid results.

                   **Ref. range**          **Hospital day 2**   **Hospital day 7**
  ---------------- ----------------------- -------------------- ----------------------
  WBC              Range: 0-- \< 5 cu mm   810 (H)              8 (H)
  RBC              Range: 0-- \< 5 cu mm   2                    90 (H)
  Protein          Range: 15--45 mg/dL     117 (H)              163 (H)
  Glucose          Range: 40--70 mg/dL     81 (H)               66
  Appearance                               Hazy                 Clear
  Lymphs                                   19% (H)              83% (H)
  Mono/macrocyte                           8% (H)               17% (H)
  Polys                                    73% (H)              
  Xanthochromia                            Clear                Xanthochromia absent
  Tube number                              3                    

###### 

Arbovirus serology panel.

                                **Ref. range**     **Hospital day 2**   **Hospital day 7**
  ----------------------------- ------------------ -------------------- --------------------
  California Encephalitis IgG   Range: \< 1:16     1:256 (H)            1:64 (H)
  California Encephalitis IgM   Range: \< 1:16     \< 1:16              \< 1:16
  East Equine IgG               Range: \< 1:16     \< 1:16              \< 1:16
  East Equine IgM               Range: \< 1:16     \< 1:16              1:512 (H)
  St Louis IgG                  Range: \< 1:16     \< 1:16              \< 1:16
  St Louis IgM                  Range: \< 1:16     \< 1:16              \< 1:16
  West Equine IgG               Range: \< 1:16     \< 1:16              \< 1:16
  West Equine IgM               Range: \< 1:16     \< 1:16              \< 1:16
  West Nile IgG                 Range: ≤ 1.29 IV   0.17                 0.17
  West Nile IgM                 Range: ≤ 0.89 IV   0.02                 0.00

![Serial MRI Brain sequences for hospital day 1, 8, and 21. On hospital day 1, there is abnormal hyperintense T2 FLAIR signal in the bilateral deep gray nuclei without associated restricted diffusion. On hospital day 8, there is progressively increasing abnormal T2 signal in the deep gray nuclei as well as restricted diffusion within the areas of abnormal T2 signal. There are no abnormalities on T1 pre and post contrast sequences. On hospital day 21, there is evolving T2 hyperintense signal in the bilateral deep gray nuclei with similar degree of restricted diffusion. There is now an abnormal T1 hyperintense signal in the deep gray nuclei without contrast enhancement, suggestive of developing gliosis.](fneur-10-00242-g0001){#F1}

Electroencephalogram (EEG) showed diffuse background slowing and rare left temporal sharp waves. On hospital day 4, neurological exam in the setting of pharmacologic sedation and mechanical ventilation was significant for a comatose state with absent brainstem reflexes except for bilateral positive corneal reflexes. She withdrew to painful stimuli in the upper extremities but not lower extremities. Continuous EEG (cEEG) eventually found evidence of non-convulsive status epilepticus (NCSE) and the patient was stabilized with levetiracetam, valproic acid, and lacosamide. Acute viral encephalitis was suspected and a 5-day course of 0.4 g/kg/day IVIg was started on hospital day 7. Results from repeat CSF arbovirus panel drawn 5 days after the first panel (hospital day 7) showed strongly positive EEE IgM titer at 1:512, and positive California encephalitis IgG at 1:64. Follow up MRI Brain with and without contrast (hospital day 8) demonstrated progressive abnormal increased T2 signal in the deep gray nuclei with restricted diffusion. There was new diffuse involvement of the cortex, most prominent in the bilateral mesial temporal lobes and the high convexities. There was also leptomeningeal and perivascular enhancement throughout the cerebral hemispheres. After completion of empirical IVIg trial, the patient continued to be in a comatose state in the absence of pharmacologic sedation. MRI Brain with and without contrast 10 days after completing IVIg (hospital day 22) showed decreased leptomeningeal and pial enhancement suggestive of decreased inflammation. There was again progressive T2 hyperintensity in the deep gray nuclei, with near complete involvement of the caudate and putamen. There were no new areas of restricted diffusion. The patient was successfully weaned off mechanical ventilation 5 weeks after empiric IVIg treatment completion. During clinic follow-up 6 weeks post-IVIg trial completion, neurological exam showed an awake state with spontaneous eye opening, presence of bilateral blink to threat, intact corneal reflexes, and withdrawal to noxious stimuli in all extremities. She was non-verbal, unable to follow simple instructions, unable to walk, and completely dependent in her activities of daily living.

Discussion {#s3}
==========

Recent case reports of possible positive outcome from empiric IVIg and high-dose IV methylprednisolone (1 g/day) in EEE suggest that a part of the neuropathology associated with EEEV infection may be due to the inflammatory reaction in the brain. EEE patients treated with IVIg were able to follow commands within 1--6 days after IVIg initiation ([@B9]--[@B11]). Many factors including timing of IVIg administration during EEE disease course may contribute to the decreased effectiveness of IVIg. Various mechanisms underlying the immunomodulatory effect of IVIg have been suggested ([@B15]). The dimeric antigen-binding fragment, F(ab\')~2~, and the constant fragment (Fc), have both been shown to be crucial for immunosuppression in IVIg therapy ([@B15]). F(ab\')2-dependent mechanisms involves inflammatory cell depletion, cellular receptors blockade, cytokines and autoantibody neutralization, and anaphylatoxin scavenging ([@B15]). Saturating the neonatal Fc receptor (FcRn), promoting expansion of regulatory T (Treg) cells, blocking activating receptor, modulating dendritic cells, blocking immune complex binding to low-affinity Fcγ receptors (FcγRs), and modulation of activating and inhibitory FcγR expression on innate immune effector cells and B cells are Fc-dependent mechanisms attributed to IVIg ([@B15]).

The clinical manifestations of multiple arbovirus infections in a single patient have not been well-characterized. This case report showed an acute seroconversion of EEEV IgM in the background of the patient\'s California serogroup encephalitis virus IgG seropositivity, the patient remained in a comatose state upon completion of IVIg therapy. She may have experienced a more severe encephalitis due to neuroinvasive EEEV coinfection on California serogroup encephalitis virus infection. Recent studies have shown that the La Crosse virus induces neuronal death through activation of innate immune signaling ([@B16]). EEEV was recently shown to avoid innate immune activation by using a host microRNA to restrict viral replication in innate immune cells, and the degree of peripheral innate immune escape is directly correlated to mortality in mice ([@B17]). Concomitant innate immune signaling activation by a California serogroup encephalitis virus and peripheral innate immune escape of EEEV in the current patient may explain the rapid progression to comatose state and decreased effectiveness of IVIg treatment.

In this patient, initial CSF serology testing showed only California serogroup encephalitis virus IgG positivity. The rapidly deteriorating clinical course of a patient presenting with encephalopathy and then progressing to comatose state within 1 day is atypical for California serogroup encephalitis, especially in adults ([@B13], [@B14]). However, a case of encephalitis and rapid cognitive decline associated with Jamestown Canyon virus, a member of the California serogroup viruses, was reported in a 73-year-old male ([@B18]). This raises the possibility of attributing the patient\'s severe clinical presentation to coinfection of EEEV and Jamestown Canyon virus as arbovirus coinfection can augment *in vivo* replication \[reviewed in Vogels et al. ([@B19])\]. Repeat CSF serology 5 days later revealed high EEEV IgM titer along with California serogroup encephalitis virus IgG. Indirect immunofluorescence assay for Rabies virus is known to have cross-reactivity with West Nile and Powassan flaviviruses ([@B20]), which raises the possibility that our detection of California serogroup encephalitis virus and EEEV could be due to cross-reactivity. However, cross-reactivity is unlikely because we detected California serogroup encephalitis virus IgG initially without EEEV IgM or IgG and EEEV IgM was only detected in the repeat CSF serology 5 days later, showing acute seroconversion of EEEV. If cross-reactivity did occur, then both EEEV IgM or IgG would be detected concomitantly with California serogroup encephalitis virus IgM or IgG in both CSF samples. Another limitation of this case report is the lack of PCR study confirming the presence of EEEV and California serogroup encephalitis virus in the patient\'s CSF. Only 3 cases of EEE with good outcomes have been reported in the setting of empiric IVIg therapy ([@B9]--[@B11]). No randomized clinical trials have examined the efficacy of IVIg in EEE, likely due to the rarity of EEE ([@B6]).

This report presents a unique case of acute EEEV seroconversion with coinfection on California serogroup encephalitis virus infection. Repeat CSF serology testing should be performed to confirm a clinical suspicion of EEE. IVIg therapy can be considered if the clinical suspicion of EEE is high though blinded randomized controlled trials are needed to establish whether IVIg has any efficacy in EEEV encephalitis. Additional research is needed to elucidate the mechanisms underlying the effect of IVIg in EEE and the disruption of such therapeutic mechanisms in the presence of multiple arbovirus disease processes.
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